Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents

Yu Liu, Wen-zhu Wan, Yan Li, Guan-lian Zhou and Xin-guang Liu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:7181-7200. https://doi.org/10.18632/oncotarget.12742

Metrics: PDF 2101 views  |   HTML 5143 views  |   ?  


Yu Liu1,2, Wen-zhu Wan1, Yan Li1, Guan-lian Zhou1 and Xin-guang Liu2

1 School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, Jinan, P. R. China

2 Department of Hematology, Qilu Hospital, Shandong University, Jinan, P. R. China

Correspondence to:

Xin-guang Liu, email:

Keywords: phosphatidylinostitol-3-kinase; PI3K; inhibitor; mTOR pathway; anticancer

Received: August 15, 2016 Accepted: October 04, 2016 Published: October 18, 2016


Phosphatidylinostitol-3-kinase (PI3K) is the potential anticancer target in the PI3K/Akt/ mTOR pathway. Here we reviewed the ATP-competitive small molecule PI3K inhibitors in the past few years, including the pan Class I PI3K inhibitors, the isoform-specific PI3K inhibitors and/or the PI3K/mTOR dual inhibitors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12742